Fingerprint
Dive into the research topics of 'Assessment of Alectinib vs Ceritinib in ALK -Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Assessment of Alectinib vs Ceritinib in ALK -Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data
Samantha Wilkinson, Alind Gupta, Nicolas Scheuer, Eric Mackay, Paul Arora, Kristian Thorlund, Radek Wasiak, Joshua Ray, Sreeram Ramagopalan, Vivek Subbiah
Research output: Contribution to journal › Article › peer-review
12
Scopus
citations